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Abstract 
Inflammation is one possible mechanism underlying the associations between mental disorders 
and cardiovascular diseases (CVD). However, studies on mental disorders and inflammation have 
yielded inconsistent results and the majority did not adjust for potential confounding factors. We 
examined the associations of several pro-inflammatory cytokines (IL-1β, IL-6 and TNF-α) and high 
sensitive C-reactive protein (hsCRP) with lifetime and current mood, anxiety and substance use 
disorders (SUD), while adjusting for multiple covariates. The sample included 3’719 subjects, 
randomly selected from the general population, who underwent thorough somatic and psychiatric 
evaluations. Psychiatric diagnoses were made with a semi-structured interview. Major depressive 
disorder was subtyped into “atypical”, “melancholic”, “combined atypical-melancholic” and 
“unspecified”. Associations between inflammatory markers and psychiatric diagnoses were 
assessed using multiple linear and logistic regression models. Lifetime bipolar disorders and 
atypical depression were associated with increased levels of hsCRP, but not after multivariate 
adjustment. After multivariate adjustment, SUD remained associated with increased hsCRP levels 
in men (β= 0.13 (95% CI: 0.03,0.23)) but not in women. After multivariate adjustment, lifetime 
combined and unspecified depression were associated with decreased levels of IL-6 (β= -0.27 (-
0.51,-0.02); β= -0.19 (-0.34,-0.05), respectively) and TNF-α (β= -0.16 (-0.30,-0.01); β= -0.10 (-
0.19,-0.02), respectively), whereas current combined and unspecified depression were associated 
with decreased levels of hsCRP (β= -0.20 (-0.39,-0.02); β= -0.12 (-0.24,-0.01), respectively). Our 
data suggest that the significant associations between increased hsCRP levels and mood 
disorders are mainly attributable to the effects of comorbid disorders, medication as well as 
behavioral and physical CVRFs. 
 
Key words: C-reactive protein; pro-inflammatory cytokines; mood disorders, depression subtypes; 
anxiety disorders; substance use disorders. 
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1. Introduction  
Chronic inflammation as part of the innate immune response has been postulated to be one 
mechanism (Baune et al., 2012; Dinan, 2009; Vogelzangs et al., 2013 ) underlying the well-
documented associations of mental disorders with cardiovascular risk factors (CVRFs) (Glaus et 
al., 2013; van Reedt Dortland et al., 2013) and cardiovascular diseases (CVD) (Baune et al., 
2012). Pro-inflammatory cytokines such as interleukin (IL)-1β, IL-6 or tumor necrosis factor (TNF)-α 
(Dowlati et al., 2010; Mota et al., 2013) induce the production of acute-phase proteins including the 
C-reactive protein (CRP) (Maes et al., 1997), which is a common marker of underlying low-grade 
inflammation (Ford & Erlinger, 2004). Cytokines and the CRP have been found to be associated 
with CVRFs such as diabetes (Marques-Vidal et al., 2012a), overweight (Marques-Vidal et al., 
2012b) and smoking (Yanbaeva et al., 2007), as well as with several mental disorders.  
The bulk of research on mental disorders and inflammatory markers has focused on major 
depressive disorder (MDD) revealing complex association pictures depending on the type of the 
sample and the covariates analyses adjusted for. A recent meta-analyses of clinical studies has 
documented higher concentrations of circulating IL-6 and TNF-α among depressed subjects 
compared to healthy controls (Liu et al., 2012), whereas a meta-analysis of a small set of 
community studies revealed inconclusive results (Kuo et al., 2005). Another meta-analysis 
including both clinical and community studies supported associations between inflammatory 
markers and depression in clinical and to a lower degree also in community studies (Howren et al., 
2009). However, the strength of these associations largely varied in function of the instruments 
used to assess depression and the covariates the analyses were adjusted for.  In several studies, 
the association between inflammation and depression was no longer statistically significant after 
adjustment for covariates, although the number of covariates considered was often limited 
(Vogelzangs et al., 2012; Duivis et al., 2011; Douglas et al., 2004). Moreover, the results of one of 
the few studies that adjusted for multiple covariates suggest that the distinction between lifetime 
and current depression is important to determine whether the increase of inflammation markers 
persists after the remission of a depressive episode (Whooley et al., 2008). In contrast to the 
expectation, this study revealed lower CRP and IL-6 levels in patients with current depression than 
3 
 
in those with lifetime depression (Whooley et al., 2008). Heterogeneity of depression (Schmidt et 
al., 2011) is another potential source of the large variety of results across previous research. 
However, the use of depression scales rather than diagnostic interviews in the large majority of 
previous studies impeded them to subtype depression. The few studies that subtyped depression 
in clinical patients generally suggested differential associations of depression subtypes with 
inflammation markers. Indeed, non-melancholic depression has been found to be associated with 
increased levels of IL-1β (Kaestner et al., 2005) and chronic atypical depression with increased 
levels of the CRP, IL-6 and TNF-α (Lamers et al., 2012), whereas melancholic patients did not 
reveal increased levels of inflammatory markers as compared to non-depressed individuals 
(Rothermundt et al., 2001). Similarly, a community based study found levels of CRP to be higher in 
subjects suffering from atypical depression compared to non-atypical and non depressive subjects, 
although there were no differences between the two latter groups (Hickman et al., 2013). In 
contrast, a recent clinical study did not provide evidence of higher levels of IL-6 and TNF-α in 
atypical as compared to melancholic depressives (Yoon et al., 2012), whereas another small 
clinical study (Rudolf et al., 2014) documented higher levels of IL-6 in patients with atypical MDD 
than in patients with typical MDD and controls. These differences remained significant after 
adjustment for weight in the latter study, whereas in the study of Lamers et al. (Lamers et al., 
2012), the between-group differences remained significant only for TNF-α but not for the CRP and 
IL-6 after adjustment for the body mass index (BMI).  
Regarding bipolar disorder, a recent meta-analysis of 30 studies also showed significant elevations 
of IL-6 and TNF-α in subjects exhibiting this disorder as compared to healthy controls 
(Modabbernia et al., 2013). Similarly, increased levels of high sensitive CRP (hsCRP) were found 
during acute episodes of mania (Cunha et al., 2008). In contrast to mood disorders, studies on the 
association between anxiety disorders or substance use disorders (SUD) and inflammatory 
markers are still rare. Recent studies revealed elevated levels of inflammatory markers in subjects 
with PTSD (von Kanel et al., 2007; Gill et al., 2009; Spitzer et al., 2010) and in male but not female 
subjects with current anxiety disorders (Vogelzangs et al., 2013), whereas decreased CRP and IL-
6 levels were observed in women with current social phobia (Vogelzangs et al., 2013). A 
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longitudinal study found generalized anxiety disorder (GAD) to be associated with an increased 
CRP level, but this association was attributable to health-related factors such as BMI and 
medication use (Copeland et al., 2012). Concerning substance use disorders (SUD), our group 
previously reported an association between moderate alcohol consumption and lower levels of IL-6 
and TNF-α (Marques-Vidal et al., 2012c), whereas a recent review concluded that the levels of pro-
inflammatory cytokines are increased in patients suffering from chronic alcoholism (Achur et al., 
2010). Among the very few studies that examined the role of other SUD, Costello et al. (Costello et 
al., 2013) showed a prospective positive association between the CRP level and any substance 
abuse or dependence in the community and Nabati et al. (Nabati et al., 2013) found some elevated 
cytokines in opium addicts (e.g. Il-6) whereas others were diminished. 
Given the and limitations and partially inconsistent findings of previous research, we aimed to 
further examine the associations between mood disorders and their subtypes, anxiety and 
substance use disorders and inflammation markers (CRP, IL-1β, IL-6, TNF-α) in the community 
with serial adjustments for a wide array of covariates including socio-demographic characteristics, 
psychotropic medication, behavioral and physical CVRFs. Separate analyses were conducted for 
lifetime and current mental disorders. 
 
2. Methods  
2.1. Study population 
The data of the present paper stem from CoLaus|PsyCoLaus (Preisig et al., 2009), a cohort study 
designed to study mental disorders and CVRFs/CVD in the general population. A total of 6’736 
individuals (CoLaus), aged between 35 and 75 years, were initially recruited in 2003 in the city of 
Lausanne (Switzerland), based on the population registry of the city. In addition to anthropometric 
measures, DNA and plasma samples were collected for the study of genetic variants and 
biomarkers associated with CVRFs (Firmann et al., 2008). Subsequently, 67% of the participants 
of the CoLaus study in the age range of 35 to 66 years (N=5’535) agreed to take part in the 
psychiatric evaluation (PsyCoLaus), which resulted in a sample of 3’719 individuals who underwent 
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both the somatic/cardiovascular and psychiatric exams (Preisig et al., 2009). Ninety-two percent 
were Caucasians. The gender distribution of the PsyCoLaus sample (47% men) did not differ 
significantly from that of the general population in the same age range (Preisig et al., 2009). 
Among these 3’719 participants, 3’527 had measures of high-sensitivity CRP (hsCRP) and 3’478 
of pro-inflammatory cytokines. Participants of PsyCoLaus and individuals who refused to 
participate had comparable scores on the General Health Questionnaire (GHQ-12 (Goldberg, 
1972); French translation (Bettschart & Bolognini, 1996)), a self-rating instrument which assessed 
psychiatric symptoms at the physical exam. 
The CoLaus and subsequently the PsyCoLaus study were both approved by the local Institutional 
Ethic’s Committee. All participants gave written informed consent after having received a detailed 
description of the goal and funding of the study. 
2.2. Measurements  
2.2.1. Psychiatric evaluation 
Mental disorders were assessed using the semi-structured Diagnostic Interview for Genetic 
Studies (DIGS (Nurnberger et al., 1994)). Interviewers were required to be master-level 
psychologists or psychiatrists, who were trained for two months. Training included rating tapes and 
supervised co-ratings. In order to provide supervision throughout the study, all interviews and 
diagnostic assignments were reviewed by an experienced senior psychologist. 
The DIGS was developed by the National Institute of Mental Health Molecular Genetics Initiative 
(NIMH) to obtain a more precise assessment of phenotypes across a wide spectrum of DSM-IV 
Axis I criteria. The DIGS was completed with sections on anxiety disorders using the questions 
from the Schedule for Affective Disorders and Schizophrenia - Lifetime Version (SADS-L (Endicott  
& Spitzer, 1978)). The original DIGS section on nicotine consumption was expanded. The French 
translation of the DIGS (Leboyer et al., 1995) revealed excellent inter-rater reliability in terms of 
kappa and Yule's Y coefficients for major mood and psychotic disorders (Preisig et al., 1999), and 
for SUD (Berney et al., 2002); the 6-week test-retest reliability was lower but still in the fair to good 
range (Berney et al., 2002; Preisig et al., 1999). The anxiety sections of the French version of the 
SADS-LA also revealed satisfactory inter-rater and test-retest reliability (Leboyer et al., 1991). 
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Information from the depression section of the DIGS allowed for the categorization of lifetime MDD 
into four subtypes (Angst et al., 2006): 1) MDD with at least one atypical and one melancholic 
episode (combined type); 2) MDD with at least one atypical (but no melancholic) episode; 3) MDD 
with at least one melancholic (but no atypical) episode; and 4) MDD with neither atypical nor 
melancholic episodes (unspecified type). For the definitions of MDD subtypes, we used the DSM-
IV specifiers in a non-hierarchical way (see (Glaus et al., 2013)).  
As the psychiatric investigation was conducted approximately one year after the somatic exam, we 
defined a current episode of depression as meeting criteria for MDD at the psychiatric evaluation 
and having a GHQ-12 score > 1, indicating clinically relevant distress at the time of the physical 
evaluation. Moreover, for the other psychiatric disorders, we considered diagnoses to be current if 
the subject described the disorder as ongoing at the time of the psychiatric investigation. Subjects 
with current diagnoses were also included in the categories of lifetime diagnoses in the present 
analyses. 
Lifetime alcohol and drug abuse and dependence diagnoses were lumped together. The subjects 
with alcohol dependence (N=178) and those with alcohol abuse (n=187) acknowledged an intake 
of 30.1 and 19.5 drinks per week, respectively, during a period of regular consumption. Subjects 
with one or more lifetime drug disorder met criteria for cocaine, heroin, stimulant, sedative or 
hallucinogen abuse or dependence. 
The DIGS also allows for the recording of information on psychotropic drug treatment over lifetime 
as well as on leisure time physical activity. The section on psychotropic drug treatment took into 
account all types of antidepressants, mood stabilizers (lithium and anti-epileptics) and all 
antipsychotics. A subject was considered to be physically inactive when there was no indication of 
regular physical exercise at least once a week at the time of the psychiatric evaluation. 
Socio-economic status (SES) was assessed using the Hollingshead scale (Hollingshead, 1975).  
2.2.2. Physical and biochemical evaluation 
HsCRP was assessed using immunoassay and latex HS (IMMULITE 1000-High, Diagnostic 
Products Corporation, LA, CA, USA), with maximum intra- and interbatch coefficients of variation of 
1.3% and 4.6%, respectively (Firmann et al., 2008). Subjects with a hsCRP level higher than 10 
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mg/l were excluded as such an elevation is likely to be attributable to acute infection (Pearson et 
al., 2003). For the cytokine measurements, serum was preferred to plasma, as it has been shown 
that different anticoagulants may differentially affect absolute cytokine levels (Skeppholm et al., 
2008). Serum samples were stored at -80°C before assessment and sent on dry ice to the 
laboratory. Cytokine levels were measured using a multiplexed particle-based flow cytometric 
cytokine assay (Marques-Vidal et al., 2011). Lower detection limits (LOD) for IL-1β, IL-6 and TNF-α 
were 0.2 pg/ml. Good agreement between signal and cytokine was found within the assay range 
(R2≥0.99).  
Anthropometric measures (body weight, height, waist and hip circumferences) were obtained to 
calculate the BMI (mass in kg divided by the height in meters raised to the square) (Firmann et al., 
2008). A diagnosis of hypertension was assigned in the case of a systolic blood pressure ≥ 140 
mmHg and/or a diastolic blood pressure ≥ 90 mmHg, or if drug treatment was prescribed for 
hypertension. Venous blood samples were drawn from each participant after an overnight fast in 
order to measure the levels of glucose, HDL-cholesterol, LDL-cholesterol and triglycerides. 
Diabetes was diagnosed when a fasting blood glucose ≥ 7mmol/l was measured or when the 
subject was treated for diabetes. Diagnostic criteria for dyslipidemia were: HDL-cholesterol < 1 
mmol/l, or LDL-cholesterol ≥ 4.1 mmol/l, or triglycerides ≥ 2.2 mmol/l, or when treated with a lipid-
lowering drug. Regular nicotine consumption was defined as a current or past history of regular 
daily consumption of at least 10 cigarettes. 
2.3. Statistical analysis 
Statistical analyses were conducted using the Statistical Analysis System, version 9.2 for Windows 
(SAS Institute Inc., Cary, NC, USA). Descriptive data for demographic characteristics, psychiatric 
disorders and inflammatory markers were derived for the total sample and by gender. 
Comparisons between men and women were conducted using Student’s t-test, Wilcoxon-Mann-
Whitney test or chi-square tests as appropriate. Associations between mental disorders and 
hsCRP, IL-6 and TNF-α outcome levels were determined using multiple linear regression models. 
Box-Cox transformation was applied to the response variable whenever a deviation from 
fundamental assumptions was observed. Values below the LOD of 0.2 [pg/ml] (i.e., 9.5% of values 
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for IL-6, 0.7% of values for TNF-α) were considered as censored observations. IL-6 and TNF-α 
were analyzed with the qualitative and limited dependent variable model (QLIM) with the threshold 
of -1.65 [log(pg/ml)] as the meaningful lower bound of observed values. Subsequently, a multiple 
linear regression was performed on log-transformed observed values. Given that as many as 
37.1% of the values of IL-1β were below the LOD, we dichotomized this variable at the median and 
applied logistic regression models. Five models of increasing complexity were computed. 
Interactions between specific mental disorders and gender were tested for all inflammation 
markers. In case of significant interactions, stratified analyses were performed by gender. A first 
series of models (Model 1) included one single mental disorder at a time as the independent 
variable, adjusted for socio-demographic characteristics (gender, age and SES). Age of subjects 
was divided by its standard deviation to improve its comparability to the other covariates (i.e. the 
OR for age described the increase in odds per increase of one standard deviation). Model 2 
included all mental disorders simultaneously in order to determine the association of specific 
mental disorders with inflammation markers, adjusting for all comorbid disorders. Model 3 was 
further adjusted for the effects of psychotropic medication (antidepressants, mood stabilizers and 
antipsychotics), Model 4 for the effects of behavioral CVRFs (physical inactivity and smoking) and 
Model 5 for all the previous covariates as well as for the well-established physical CVRFs (BMI, 
diabetes, dyslipidemia and hypertension). P-values were not adjusted for multiple testing because 
the hypothesized associations between mental disorders and inflammatory markers were specified 
a priori. 
 
3. Results 
The characteristics of the participants are presented in Table 1. Women were older than men, had 
a lower SES, lower levels of IL-6 and TNF-α, and higher lifetime rates of MDD, MDD subtypes and 
anxiety disorders. A similar pattern emerged for current mental disorders, except for unspecified 
MDD where no gender differences were observed. In contrast, women had less lifetime and 
current SUD than men 
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All covariates used as adjustments in the models, except for psychotropic medications, were 
associated with pro-inflammatory cytokines or hsCRP (table e-1 published online). First, 
associations between lifetime or current mental disorders and inflammatory markers adjusted only 
for socio-demographic characteristics are presented in Table 2. Significant interactions between 
mental disorders and gender emerged for lifetime bipolar disorder (BPD) regarding IL-6 (β=0.99, 
95% CI: (0.20,1.78); men: β=-0.83, (-1.35,-0.31); women: β=0.16, (-0.43,0.75)) and SUD regarding 
hsCRP levels (β=-0.32, (-0.52,-0.12); men: β=0.19, (0.09,0.30); women: β=-0.13, (-0.31,0.04)). In 
addition, lifetime BPD and the atypical MDD subtype were associated with increased levels of 
hsCRP. The hsCRP level in subjects exhibiting the lifetime atypical MDD subtype was significantly 
higher than those with the other MDD subtypes as indicated by the β-estimate, which lay above the 
upper bound of the 95% confidence interval of the estimates for all the other MDD subtypes. In 
contrast, lifetime and current anxiety disorders were associated with decreased levels of hsCRP. 
Neither the IL-1β nor the TNF-α revealed associations with lifetime or current mental disorders. 
Similar to the models adjusted for socio-demographic characteristics, the models adjusted for the 
other covariates (Model 2 to Model 5: Tables 3 and 4) revealed significant interactions by gender: 
lifetime BPD regarding IL-6 (Model 5: interaction term β= 0.98, (0.15,1.80) and SUD regarding 
hsCRP levels (Model 5: β= -0.29, (-0.48,-0.10)). Indeed, men compared to women with lifetime 
BPD had decreased IL-6 levels (β= -0.84, (-1.45,-0.24) vs. β= -0.13, (-0.76,0.50)), whereas men 
compared to women with lifetime SUD had increased hsCRP levels (β= 0.13, (0.03,0.23) vs. β= -
0.11, (-0.27,0.06)). 
In addition, decreased levels of IL-6 and TNF-α were found to be associated with some mental 
disorders (Tables 3 and 4). Indeed, lifetime BPD was found to be associated with decreased levels 
of TNF-α even after full adjustments. Furthermore, BPD was associated with increased levels of 
hsCRP, but no longer after adjustment for physical CVRFs. The combined MDD subtype was 
associated with a decreased level of IL-6 after full adjustments, and with a decreased level of TNF-
α when the model was adjusted for behavioral and physical CVRFs. Unspecified MDD was 
associated with decreased levels of IL-6 and TNF-α in all four models, whereas lifetime atypical 
MDD was no longer associated with hsCRP in any of the four models. Finally, lifetime anxiety 
disorders were still associated with decreased levels of hsCRP but no longer after adjustment for 
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physical CVRFs. Concerning the associations between current mental disorders and inflammatory 
markers (Table 4), pro-inflammatory cytokines were not associated with any mental disorder. 
However, combined MDD was associated with lower levels of hsCRP in the final model. 
Melancholic and anxiety disorders were associated with decreased levels of hsCRP until Model 4, 
but no longer after adjustment for physical CVRFs (Model 5). Unspecified MDD remained 
negatively associated with hsCRP throughout Models 2 to 5. Finally, associations between pro-
inflammatory markers and a current diagnosis of BPD could not be assessed due to the small 
sample size. 
 
 
4. Discussion 
The present study is, to our knowledge, the first to simultaneously assess the associations 
between several inflammatory markers and a large array of DSM-IV Axis-I disorders and subtypes 
of MDD in the community with serial adjustments for multiple covariates. The study has revealed 
complex association patterns between mental disorders and inflammatory markers, which have 
shown a large variance across disorders and differed partially according to gender and the 
covariates adjusted for. The major findings, which were more prominent using lifetime than current 
diagnoses, were: 1) the associations between lifetime BPD or the atypical MDD subtype with 
increased hsCRP levels are no longer statistically significant after adjustment for multiple 
covariates; 2) lifetime BPD is associated with lower IL-6 levels in men and with lower TNF-α levels 
in both genders after adjustment for covariates; 3) the combined and unspecified subtypes of 
lifetime MDD are also associated with lower levels of IL-6 and TNF-α, and 4) lifetime SUD is 
associated with increased hsCRP levels in men but not in women. 
 
4.1. BPD and inflammation 
Our data provided evidence for positive and negative associations between BPD and inflammatory 
markers. First, BPD was associated with lower TNF-α levels after adjustment for multiple 
covariates and with lower IL-6 levels in men. Conversely, we observed a positive association 
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between BPD and hsCRP levels. However, the cross-sectional nature of our data precludes 
conclusions regarding the direction of causality. Accordingly, the fact that the association between 
BPD and hsCRP levels was no longer statistically significant after adjustment for physical CVRFs 
could be explained by an increase of inflammation markers in bipolar subjects either as a 
consequence of or as a predisposing factor to physical CVRFs. 
 
4.2. Depression and inflammation 
Our community data provide partial support to recent clinical findings (Kaestner et al., 2005; 
Lamers et al., 2012; Rothermundt et al., 2001; Rudolf et al., 2014) that suggested differential 
associations between subtypes of MDD and inflammatory markers. Indeed, after adjustment for 
demographic factors, subjects exhibiting the atypical MDD subtype revealed higher hsCRP levels 
than those with other depression subtypes or without depression. However, similar to the study of 
Lamers et al (Lamers et al., 2012), which relied on severely affected patients with chronic 
depression, this association was no longer statistically significant after adjustment for multiple 
covariates including physical CVRFs. Accordingly, atypical depression could contribute to 
inflammation via facilitating adverse health behaviors or the accumulation of physical CVRFs, 
which have been shown to be associated with elevated inflammation (Marques-Vidal et al., 2012b; 
Marques-Vidal et al., 2012d; Lamers et al., 2012). The lower magnitude of the association between 
depression and inflammation markers after adjustment for CVRFs including BMI is also in line with 
a recent meta-analysis (Howren et al., 2009). However, the cross-sectional design of the present 
study does not allow us to assess the temporal sequence of the onset of depression subtypes, the 
increase of inflammation markers and the onset of CVRFs and to determine the role of 
inflammation in the strong association between the atypical depression subtype and CVRFs. 
Indeed, a third variable (covariate) such as BMI could be 1) a mediator of the association (atypical 
depression could lead to increase weight, which is associated with elevated inflammatory 
markers), 2) a confounder (an elevated BMI could predispose to both depression and elevated 
inflammatory markers), 3) a consequence of elevated inflammatory markers (if elevated 
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inflammatory markers predisposes to BMI increase), or 4) a condition predisposing to the mental 
disorder (elevated BMI could predispose to depression).  
Interestingly, after adjustment for multiple covariates in our study the combined and unspecified 
MDD subtypes revealed negative associations with IL-6 and TNF-α, whereas the other MDD 
subtypes were not associated with any inflammatory markers. At least two previous studies already 
provided evidence for decreased levels of cytokines in depressed subjects (Whooley et al., 2008; 
Rothermundt et al., 2001). One explanation is that this could be due to decreased levels of 
monocytes found in depressed patients (Whooley et al., 2008). Secretion of IL-6 by monocytes is a 
major source of IL-6 concentration that can be measured in the circulation (Whooley et al., 2008). 
Another potential explanation is that elevated levels of cortisol are found in depressed compared to 
non-depressed subjects (Burke et al., 2005), and it is well known that cortisol has anti-inflammatory 
properties (Duivis et al., 2011). Elevated cortisol levels might particularly suppress pro-
inflammatory cytokine production (Hansel et al., 2010).  
 
4.3. Anxiety disorders and inflammation 
In contrast to a previous clinical study (Vogelzangs et al., 2013), anxiety disorders were associated 
with lower hsCRP levels in our sample. However, this association was no longer statistically 
significant after adjustment for physical CVRFs, which suggests that this association is attributable 
to the low BMI of subjects with anxiety disorders (Glaus et al., 2013) and the strong positive 
association between the BMI and the hsCRP. The potential mediating effect of health-related 
factors in the association between anxiety disorders and CRP levels is consistent with findings of a 
previous community study (Copeland et al., 2012). 
 
4.4. SUD and inflammation 
The association between SUD and an increased hsCRP level remained significant in men even 
after multiple adjustments, which is in line with previous findings regarding increased levels of 
inflammation markers in alcoholics (Achur et al., 2010) and subjects with cannabis abuse or 
dependence (Costello et al., 2013). In drinkers, the increased level of pro-inflammatory cytokines 
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has been shown to be associated with chronic and acute alcohol-induced lever diseases, but also 
with a significant increase in spontaneous cytokine production (Achur et al., 2010). Similarly, 
chronic exposure to drugs may favor cytokine expression in the brain (Yamada 2008). Conversely, 
as suggested by the prospective community study of Costello et al. (Costello et al., 2013) a high 
CRP level is also a predictor of SUD. 
4.5. Limitations 
The results of the present study should be considered in the context of several limitations. First, the 
cross-sectional nature of the study precluded any statements about causality of the link between 
the studied mental disorders and inflammatory processes. Second, the use of a sample recruited in 
the general population limited our ability to study associations between inflammation markers and 
severe forms of mental illness (disorders that require inpatient or specialty clinics treatment), which 
are rare in the community. Third, we had to determine the presence of a current depression at the 
time of the assessment of inflammation using the GHQ scale, given the one-year interval between 
the assessment of inflammatory markers and the psychiatric evaluation. 
 
4.6. Conclusion 
In conclusion, our data suggest that the significant associations between increased hsCRP levels 
and BPD and the atypical MDD subtype, which were no longer statistically significant after 
adjustment for multiple covariates, are mainly attributable to the effects of comorbid disorders, 
medication as well as behavioral and physical CVRFs. Moreover, after adjustment for multiple 
covariates our data also provide evidence for negative associations between the combined and the 
unspecified MDD subtypes and inflammatory markers. Only SUD in men remained significantly 
associated with increased hsCRP levels after multivariate adjustment. Prospective studies are 
required to further elucidate the role of hsCRP levels in the complex association between mood 
disorders or SUD and CVRFs/CVD. 
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Table e-1: Levels of pro-inflammatory proteins and covariates 
        Interleukin-1β [pg/l]   Interleukin-6 [pg/ml]   TNF-α [pg/ml]   hsCRP [mg/l] 
    N   Median IQR pa   Median IQR pa   Median IQR pa   N Median IQR pa 
Demographic characteristics                                     
Gender Men 1640  0.39 (0.10,1.73)   1.42 (0.63,3.50)   2.92 (1.86,4.58)   1684 1.00 (0.50,2.10)  
 Women 1838  0.49 (0.10,2.00) 0.050  1.19 (0.49,3.12) 0.001  2.64 (1.63,4.26) <0.001  1843 1.10 (0.50,2.40) 0.491 
Age    -0.08  <.0001b  0.06  0.001b  0.11  <.000 b   0.17  <.000 b 
SES    0.00  0.853b  -0.02  0.16 b  -0.01  0.388 b   -0.14  <.000 b 
                    
Lifetime diagnoses                                     
Bipolar No 3416  0.44 (0.10,1.96)  
 1.28 (0.56,3.30)  
 2.80 (1.75,4.47)  
 3461 1.00 (0.50,2.20)  
 Yes 62  0.38 (0.10,0.91) 0.500  1.17 (0.35,2.59) 0.113  2.45 (1.55,3.88) 0.099  66 1.30 (0.70,3.10) 0.017 
Dysthymia No 3404  0.44 (0.10,1.94)  
 1.28 (0.56,3.29)  
 2.78 (1.74,4.45)  
 3449 1.10 (0.50,2.30)  
 Yes 74  0.36 (0.10,2.35) 0.423  1.22 (0.45,2.60) 0.486  3.20 (2.01,5.09) 0.269  78 0.90 (0.50,1.90) 0.343 
MDD No 1969  0.45 (0.10,1.94)  
 1.34 (0.59,3.38)  
 2.87 (1.85,4.47)  
 1995 1.10 (0.50,2.30)  
 Yes 1509  0.42 (0.10,1.92) 0.250  1.20 (0.50,3.16) 0.036  2.69 (1.62,4.34) 0.004  1532 1.00 (0.50,2.25) 0.161 
  Combined MDD No 3275  0.44 (0.10,1.93)  
 1.29 (0.56,3.27)  
 2.81 (1.76,4.46)  
 3324 1.10 (0.50,2.30)  
 Yes 203  0.38 (0.10,2.11) 0.837  1.15 (0.61,3.12) 0.464  2.48 (1.59,4.09) 0.091  203 1.00 (0.50,2.30) 0.927 
  Atypical MDD No 3261  0.44 (0.10,1.94)  
 1.27 (0.56,3.24)  
 2.77 (1.74,4.42)  
 3309 1.00 (0.50,2.20)  
 Yes 217  0.37 (0.10,1.86) 0.777  1.49 (0.50,4.09) 0.290  2.96 (1.78,4.91) 0.253  218 1.20 (0.60,2.60) 0.096 
  Melancholic MDD No 3059  0.44 (0.10,1.94)  
 1.28 (0.56,3.31)  
 2.80 (1.76,4.46)  
 3104 1.10 (0.50,2.20)  
 Yes 419  0.42 (0.10,1.94) 0.812  1.24 (0.54,2.87) 0.521  2.75 (1.61,4.32) 0.313  423 1.00 (0.50,2.30) 0.383 
  Unspecified MDD No 2808  0.44 (0.10,1.94)  
 1.32 (0.59,3.29)   2.83 (1.78,4.47)   2839 1.10 (0.50,2.30)  
 Yes 670  0.43 (0.10,1.92) 0.340  1.12 (0.45,3.06) 0.021  2.61 (1.59,4.29) 0.013  688 1.00 (0.50,2.10) 0.046 
Anxiety disorders any No 2848  0.45 (0.10,1.98)  
 1.29 (0.57,3.30)  
 2.81 (1.76,4.43)  
 2896 1.10 (0.50,2.30)  
 Yes 630  0.42 (0.10,1.82) 0.489  1.24 (0.50,3.18) 0.198  2.66 (1.69,4.49) 0.318  631 1.00 (0.50,2.10) 0.019 
Substance use disorders No 2939  0.44 (0.10,1.94)  
 1.26 (0.54,3.16)   2.75 (1.73,4.36)   2976 1.00 (0.50,2.20)  
 Yes 539  0.43 (0.10,1.77) 0.954  1.43 (0.64,3.78) 0.030  2.98 (1.78,4.76) 0.041  551 1.10 (0.60,2.40) 0.173 
                    
Current diagnoses                                     
Bipolar No 3476  0.44 (0.10,1.94)   1.28 (0.56,3.27)   2.79 (1.75,4.45)   3525 1.10 (0.50,2.30)  
 Yes 2  0.25 (0.10,0.39) 0.404  2.30 (2.21,2.39) 0.411  1.18 (1.04,1.31) 0.062  2 5.50 (3.40,7.60) 0.040 
Dysthymia No 3458  0.44 (0.10,1.94)  
 1.28 (0.56,3.26)  
 2.79 (1.74,4.44)  
 3508 1.10 (0.50,2.30)  
 Yes 20  0.46 (0.10,1.64) 0.970  1.86 (0.66,7.97) 0.265  3.23 (1.89,5.34) 0.438  19 0.90 (0.70,2.60) 0.962 
MDD No 2838  0.42 (0.10,1.88)   1.27 (0.56,3.24)   2.81 (1.76,4.42)   2907 1.10 (0.50,2.30)  
 Yes 640  0.48 (0.10,2.13) 0.386  1.34 (0.60,3.49) 0.357  2.72 (1.66,4.51) 0.639  620 0.95 (0.50,2.20) 0.022 
  Combined MDD No 3376  0.44 (0.10,1.94)  
 1.29 (0.56,3.27)  
 2.80 (1.75,4.45)  
 3429 1.10 (0.50,2.30)  
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 Yes 102  0.38 (0.10,1.95) 0.409  1.14 (0.63,2.74) 0.475  2.46 (1.62,4.17) 0.358  98 0.95 (0.50,2.10) 0.783 
  Atypical MDD No 3382  0.44 (0.10,1.96)  
 1.27 (0.56,3.25)  
 2.78 (1.75,4.43)  
 3437 1.10 (0.50,2.20)  
 Yes 96  0.40 (0.10,1.48) 0.742  1.67 (0.75,4.30) 0.121  3.10 (1.69,4.95) 0.354  90 1.20 (0.60,2.60) 0.204 
  Melancholic MDD No 3287  0.43 (0.10,1.90)  
 1.28 (0.56,3.27)  
 2.79 (1.74,4.45)  
 3339 1.10 (0.50,2.30)  
 Yes 191  0.52 (0.10,2.34) 0.092  1.38 (0.54,3.04) 0.716  2.81 (1.85,4.45) 0.832  188 0.90 (0.40,2.10) 0.048 
  Unspecified MDD No 3227  0.43 (0.10,1.90)  
 1.28 (0.56,3.24)  
 2.81 (1.75,4.44)  
 3283 1.10 (0.50,2.30)  
 Yes 251  0.48 (0.10,2.44) 0.575  1.28 (0.56,3.79) 0.586  2.64 (1.61,4.52) 0.381  244 0.90 (0.40,2.10) 0.022 
Anxiety disorders any No 3126  0.43 (0.10,1.95)  
 1.29 (0.57,3.29)  
 2.80 (1.75,4.43)  
 3176 1.10 (0.50,2.30)  
 Yes 352  0.45 (0.10,1.84) 0.902  1.19 (0.48,3.13) 0.125  2.62 (1.68,4.50) 0.359  351 1.00 (0.50,2.00) 0.019 
Substance use disorders No 3257  0.44 (0.10,1.96)   1.27 (0.55,3.21) 
 
 2.77 (1.75,4.38)   3310 1.00 (0.50,2.30)  
 Yes 221  0.35 (0.10,1.62) 0.428  1.56 (0.71,4.32) 0.025  3.22 (1.76,5.11) 0.055  217 1.30 (0.60,2.20) 0.116                     
Psychotropic medication                                     
Antidepressants No 2759  0.43 (0.10,1.94)   1.27 (0.55,3.20)   2.79 (1.75,4.45)   2809 1.00 (0.50,2.20)  
 Yes 719  0.45 (0.10,1.92) 0.691  1.33 (0.62,3.59) 0.157  2.79 (1.74,4.40) 0.989  718 1.10 (0.60,2.40) 0.179 
Mood stabilizers No 3451  0.43 (0.10,1.94)  
 1.28 (0.56,3.27)  
 2.79 (1.75,4.45)  
 3500 1.10 (0.50,2.30)  
 Yes 27  0.50 (0.10,1.73) 0.643  1.49 (0.31,2.87) 0.648  3.28 (1.42,4.45) 0.922  27 1.20 (0.60,2.10) 0.594 
Antipsychotics No 3412  0.44 (0.10,1.94)  
 1.28 (0.56,3.24)  
 2.78 (1.75,4.43)  
 3463 1.00 (0.50,2.30)  
 Yes 66  0.46 (0.10,1.86) 0.947  1.42 (0.44,4.77) 0.615  3.21 (1.76,5.06) 0.385  64 1.45 (0.80,2.40) 0.065 
                    
Behavioral CVRFs                                     
Physical inactivity No 2421  0.44 (0.10,1.99)  
 1.23 (0.52,3.15)   2.76 (1.74,4.35)  
 2446 1.00 (0.50,2.10)  
 Yes 1057  0.42 (0.10,1.82) 0.425  1.43 (0.67,3.63) 0.003  2.82 (1.75,4.66) 0.189  1081 1.30 (0.60,2.70) <0.001 
Smoking No 1916  0.46 (0.10,1.94)  
 1.15 (0.50,2.87)   2.70 (1.69,4.27)   1968 1.00 (0.50,2.00)  
 Yes 1562  0.42 (0.10,1.93) 0.941  1.48 (0.65,3.90) <0.001  2.90 (1.85,4.73) 0.001  1559 1.20 (0.60,2.60) <0.001 
                    
Physical CVRFs                                     
Overweight/Obese No 1804  0.49 (0.10,2.11)   1.12 (0.47,3.07) 
 
 2.61 (1.66,4.14) 
 
 1857 0.70 (0.40,1.40) 
 
 Yes 1674  0.39 (0.10,1.70) 0.045  1.46 (0.68,3.47) <0.001  3.00 (1.85,4.76) <0.001  1670 1.60 (0.80,3.10) <0.001 
Diabetes No 3291  0.46 (0.10,1.99)   1.26 (0.55,3.24)   2.77 (1.73,4.40)   3350 1.00 (0.50,2.20)  
 Yes 187  0.10 (0.10,0.86) <0.001  1.72 (0.86,3.68) 0.004  3.31 (2.06,5.20) 0.009  177 1.80 (0.90,3.30) <0.001 
Dyslipidemia No 2350  0.46 (0.10,2.03)   1.19 (0.52,3.15) 
 
 2.70 (1.66,4.26) 
 
 2393 0.90 (0.50,2.00) 
 
 Yes 1128  0.39 (0.10,1.74) 0.036  1.45 (0.66,3.40) 0.001  3.01 (1.90,4.79) <0.001  1134 1.40 (0.70,2.70) <0.001 
Hypertension No 2432  0.49 (0.10,2.04)   1.20 (0.50,3.17) 
 
 2.66 (1.68,4.27) 
 
 2490 0.90 (0.50,1.90) 
 
  Yes 640   0.32 (0.10,1.69) <0.001   1.52 (0.68,3.45) <0.001   3.11 (1.95,4.90) <0.001   1037 1.50 (0.80,3.00) <0.001 
Key: a Wilcoxon Mann-Whitney test; b Spearman coefficient correlation; TNF-α = Tumor Necrosis Factor-α; hsCRP = high sensitivity C-Reactive Protein; IQR = interquartile range; SES = socio-economic status; 
MDD = major depressive disorder; CVRF = cardiovascular risk factor. 
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Table 1: Sample characteristics (n=3'719) 
Variables 
PsyCoLaus sample 
p 
Overall Men Women 
Demographic               
n (%) 3’719 1’749 (47.03) 1’970 (52.97)  -- 
Age, mean (SD) 50.93 (8.78) 50.51 (8.78) 51.31 (8.77) 0.006 
SES, mean (SD) 3.38 (1.28) 3.54 (1.25) 3.23 (1.28) <.0001 
Lifetime psychiatric disorders, n (%)               
Bipolar disorder 69 (1.86) 36 (2.06) 33 (1.68) 0.39 
Dysthymia 81 (2.18) 37 (2.12) 44 (2.23) 0.81 
MDD 1624 (43.67) 563 (32.19) 1061 (53.86) <.0001 
Combined MDD 219 (5.89) 60 (3.43) 159 (8.07) <.0001 
Atypical MDD 235 (6.32) 69 (3.95) 166 (8.43) <.0001 
Melancholic MDD 449 (12.07) 152 (8.69) 297 (15.08) <.0001 
Unspecified MDD 721 (19.39) 282 (16.12) 439 (22.28) <.0001 
Anxiety disorders 660 (17.85) 225 (12.95) 435 (22.19) <.0001 
SUD 573 (15.47) 428 (24.57) 145 (7.39) <.0001 
Without diagnoses 1466 (39.42) 799 (45.68) 667 (33.86) <.0001 
Current psychiatric disorders, n (%)               
Bipolar disorder 2 (0.05) 1 (0.06) 1 (0.05) 0.93 
Dysthymia 20 (0.54) 6 (0.34) 14 (0.71) 0.13 
MDD 660 (17.75) 235 (13.44) 425 (21.57) <.0001 
Combined MDD 106 (2.85) 29 (1.66) 77 (3.91) <.0001 
Atypical MDD 98 (2.64) 31 (1.77) 67 (3.40) 0.002 
Melancholic MDD 198 (5.32) 66 (3.77) 132 (6.70) <.0001 
Unspecified MDD 258 (6.94) 109 (6.23) 149 (7.56) 0.11 
Anxiety disorders 370 (9.95) 118 (6.75) 252 (12.79) <.0001 
SUD 229 (6.16) 174 (9.95) 55 (2.79) <.0001 
Without diagnoses 3059 (82.25) 1514 (86.56) 1545 (78.43) <.0001 
Inflammatory markers, median (IQR)               
IL-1β [pg/ml] 0.44 (0.10-1.94) 0.39 (0.10-1.73) 0.49 (0.10-2.00) 0.05 
IL-6 [pg/ml] 1.28 (0.56-3.27) 1.42 (0.63-3.50) 1.19 (0.49-3.12) <.001 
TNF-α [pg/ml] 2.79 (1.75-4.45) 2.92 (1.86-4.58) 2.64 (1.63-4.26) <.0001 
hsCRP [mg/l] 1.10 (0.50-2.30) 1.00 (0.50-2.10) 1.10 (0.50-2.40) 0.49 
Key: SD = standard deviation; SES = socio-economic status. A value of 3 represents an SES of III (middle class) on the Hollingshead Scale; MDD = major 
depressive disorder; SUD = substance use disorders; IQR = Inter-quartile range (the 25% and 75% quartiles are provided); IL-1β = Interleukin-1β; IL-6 = 
Interleukin-6; TNF-α = Tumor Necrosis Factor-α; hsCRP = high sensitivity C-reactive protein; Median and IQR of inflammatory markers were not 
logarithmically transformed (n Il-1β, IL-6, TNF-α=3478, 1640 men/1838 women; n hsCRP=3527, 1684 men/1843 women). 
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Table 2: Associations between lifetime and current disorders and pro-inflammatory proteins 
  Interleukin-1β [pg/l]a  Interleukin-6 [pg/ml]b  TNF-α [pg/ml]b  hsCRP [mg/l]b 
  OR 95% CI p  β 95% CI p  β 95% CI p  β 95% CI p 
Lifetime diagnoses                 
Bipolar  0.82 (0.49,1.36) 0.443  c-- -- --  -0.19 (-0.42,0.05) 0.119  0.33 (0.09,0.56) 0.008 
Dysthymia  0.82 (0.51,1.31) 0.401  -0.13 (-0.50,0.24) 0.478  0.00 (-0.21,0.22) 0.984  -0.09 (-0.31,0.13) 0.421 
MDD  0.91 (0.79,1.05) 0.194  -0.07 (-0.18,0.04) 0.186  -0.04 (-0.10,0.02) 0.207  -0.02 (-0.09,0.04) 0.494 
Combined MDD  0.90 (0.68,1.20) 0.484  -0.08 (-0.30,0.15) 0.510  -0.07 (-0.20,0.06) 0.290  -0.01 (-0.15,0.13) 0.910 
Atypical MDD  0.90 (0.68,1.19) 0.463  0.16 (-0.06,0.38) 0.158  0.11 (-0.02,0.24) 0.100  0.14 (0.01,0.28) 0.038 
Melancholic MDD  0.99 (0.81,1.22) 0.918  -0.04 (-0.21,0.12) 0.606  -0.01 (-0.11,0.08) 0.785  -0.04 (-0.14,0.06) 0.407 
Unspecified MDD  0.95 (0.80,1.12) 0.520  -0.12 (-0.25,0.02) 0.094  -0.07 (-0.15,0.01) 0.088  -0.06 (-0.14,0.03) 0.178 
Anxiety disorders any  0.88 (0.74,1.05) 0.156  -0.08 (-0.22,0.06) 0.270  0.00 (-0.08,0.08) 0.958  -0.11 (-0.19,-0.02) 0.013 
Substance use disorders  0.99 (0.82,1.20) 0.900  0.11 (-0.04,0.26) 0.141  0.06 (-0.03,0.15) 0.180  c-- -- -- 
Others  1.12 (0.98,1.29) 0.109  0.05 (-0.06,0.16) 0.337  0.04 (-0.02,0.10) 0.207  0.02 (-0.05,0.08) 0.611                  
Current diagnoses                 
Bipolar  -- -- --  -- -- --  -- -- --  -- -- -- 
Dysthymia  0.83 (0.34,2.02) 0.688  0.51 (-0.19,1.21) 0.157  0.15 (-0.25,0.56) 0.458  0.03 (-0.41,0.47) 0.894 
MDD  1.01 (0.85,1.20) 0.891  0.10 (-0.04,0.24) 0.151  0.01 (-0.07,0.09) 0.877  -0.08 (-0.17,0.01) 0.067 
Combined MDD  0.80 (0.53,1.19) 0.262  -0.13 (-0.44,0.19) 0.425  -0.07 (-0.25,0.12) 0.483  -0.04 (-0.23,0.16) 0.708 
Atypical MDD  0.93 (0.62,1.39) 0.715  0.27 (-0.05,0.59) 0.101  0.07 (-0.12,0.26) 0.459  0.19 (-0.01,0.40) 0.063 
Melancholic MDD  1.17 (0.87,1.57) 0.292  0.10 (-0.14,0.33) 0.418  0.05 (-0.09,0.18) 0.508  -0.14 (-0.28,0.00) 0.056 
Unspecified MDD  1.03 (0.80,1.34) 0.811  0.09 (-0.11,0.30) 0.366  -0.02 (-0.14,0.10) 0.716  -0.13 (-0.25,0.00) 0.050 
Anxiety disorders any  0.94 (0.75,1.17) 0.574  -0.12 (-0.29,0.06) 0.197  0.00 (-0.10,0.10) 1.000  -0.13 (-0.24,-0.03) 0.015 
Substance use disorders  0.93 (0.71,1.23) 0.630  0.19 (-0.03,0.41) 0.093  0.07 (-0.05,0.20) 0.254  0.12 (-0.01,0.26) 0.074 
Others  0.99 (0.83,1.18) 0.891  -0.10 (-0.24,0.04) 0.151  -0.01 (-0.09,0.07) 0.877  0.08 (-0.01,0.17) 0.067 
Key: a logistic regression with Intreleukin-1 beta concentration dichotomized at the median (n=3478); b multiple regression with logarithmically transformed cytokine (n=3478) or CRP 
concentrations (n=3527); c results not reported here because of a gender interaction; TNF-α = Tumor Necrosis Factor-α; hsCRP = High sensitivity C-Reactive Protein; OR = odds ratio;  
CI = confidence interval; MDD = major depressive disorder;  
Associations between pro-inflammatory markers and a current diagnosis of bipolar disorder could not be assessed due to small sample size; 
A model for each mental disorder was run separately adjusting for socio-demographic variables (age, gender and socio-economic status). 
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Table 3: Associations between lifetime mental disorders and pro-inflammatory proteins 
 
Interleukin-1β [pg/l] 
ORa 
95% CI 
p 
Interleukin-6 [pg/ml] 
βb 
95% CI 
p 
Tumor Necrosis Factor-α [pg/ml] 
βb 
95% CI 
p 
hsC-Reactive Protein [mg/l] 
βb 
95% CI 
p 
 Model 1 Model 2 Model 3 Model 4 Model 1 Model 2 Model 3 Model 4 Model 1 Model 2 Model 3 Model 4 Model 1 Model 2 Model 3 Model 4 
AIC 4811 4817 4819 4816 12642 12640 12622 12605 9363 9364 9357 9348 9853 9858 9808 9250 
Lifetime 
diagnoses 
               
BPD 0.80 0.75 0.75 0.75 c-- -- -- -- -0.22 -0.27 -0.28 -0.29 0.34 0.32 0.31 0.22 
 (0.48,1.34) (0.43,1.30) (0.43,1.30) (0.43,1.30) -- -- -- -- (-0.45,0.02) (-0.52,-0.01) (-0.53,-0.03) (-0.54,-0.04) (0.09,0.58) (0.07,0.58) (0.06,0.57) (-0.01,0.46) 
 0.396 0.298 0.308 0.302 -- -- -- -- 0.069 0.038 0.030 0.023 0.006 0.014 0.016 0.064 
Dysth 0.78 0.78 0.78 0.77 -0.19 -0.20 -0.21 -0.20 -0.03 -0.04 -0.04 -0.04 -0.09 -0.10 -0.10 -0.04 
 (0.48,1.24) (0.48,1.24) (0.49,1.25) (0.48,1.24) (-0.56,0.18) (-0.58,0.17) (-0.59,0.16) (-0.57,0.17) (-0.24,0.19) (-0.25,0.18) (-0.26,0.17) (-0.25,0.18) (-0.32,0.13) (-0.32,0.12) (-0.32,0.12) (-0.25,0.16) 
 0.291 0.291 0.296 0.282 0.313 0.282 0.256 0.287 0.795 0.743 0.711 0.741 0.403 0.385 0.359 0.679 
Comb 
MDD 0.87 0.86 0.86 0.87 -0.13 -0.22 -0.24 -0.27 -0.10 -0.14 -0.15 -0.16 0.00 -0.02 -0.03 -0.08 
 (0.65,1.17) (0.63,1.17) (0.64,1.18) (0.64,1.19) (-0.36,0.11) (-0.46,0.02) (-0.48,0.01) (-0.51,-0.02) (-0.24,0.04) (-0.28,0.00) (-0.29,-0.01) (-0.30,-0.01) (-0.14,0.15) (-0.17,0.13) (-0.18,0.12) (-0.22,0.05) 
 0.352 0.335 0.352 0.378 0.291 0.078 0.056 0.031 0.150 0.053 0.042 0.031 0.963 0.816 0.695 0.236 
Atyp 
MDD 0.86 0.85 0.86 0.88 0.10 0.03 0.03 -0.02 0.07 0.04 0.04 0.03 0.14 0.13 0.10 0.00 
 (0.65,1.15) (0.64,1.14) (0.64,1.15) (0.66,1.18) (-0.13,0.32) (-0.20,0.26) (-0.21,0.26) (-0.25,0.21) (-0.06,0.20) (-0.09,0.18) (-0.09,0.18) (-0.11,0.16) (0.00,0.28) (-0.02,0.27) (-0.04,0.24) (-0.14,0.13) 
 0.308 0.287 0.304 0.395 0.410 0.787 0.829 0.888 0.295 0.513 0.529 0.700 0.052 0.083 0.151 0.942 
Mela 
MDD 0.94 0.93 0.93 0.93 -0.10 -0.17 -0.17 -0.16 -0.04 -0.08 -0.08 -0.07 -0.03 -0.05 -0.05 -0.01 
 (0.76,1.17) (0.74,1.17) (0.74,1.17) (0.74,1.17) (-0.27,0.08) (-0.35,0.01) (-0.35,0.01) (-0.34,0.02) (-0.14,0.06) (-0.18,0.03) (-0.18,0.03) (-0.17,0.04) (-0.14,0.07) (-0.16,0.06) (-0.16,0.06) (-0.11,0.10) 
 0.600 0.536 0.534 0.508 0.279 0.062 0.061 0.089 0.382 0.158 0.158 0.193 0.542 0.397 0.416 0.901 
Unsp 
MDD 0.91 0.90 0.91 0.91 -0.15 -0.19 -0.20 -0.19 -0.09 -0.10 -0.11 -0.10 -0.04 -0.05 -0.06 -0.04 
 (0.76,1.09) (0.75,1.09) (0.76,1.09) (0.75,1.09) (-0.29,-0.01) (-0.33,-0.04) (-0.35,-0.06) (-0.34,-0.05) (-0.17,0.00) (-0.19,-0.02) (-0.19,-0.02) (-0.19,-0.02) (-0.13,0.04) (-0.14,0.04) (-0.15,0.03) (-0.12,0.04) 
 0.302 0.286 0.304 0.290 0.042 0.012 0.007 0.009 0.044 0.018 0.013 0.016 0.333 0.254 0.179 0.371 
ADA 0.90 0.90 0.90 0.90 -0.06 -0.07 -0.08 -0.06 0.01 0.00 0.00 0.01 -0.12 -0.12 -0.13 -0.08 
 (0.75,1.07) (0.75,1.07) (0.75,1.08) (0.75,1.08) (-0.20,0.08) (-0.21,0.07) (-0.22,0.06) (-0.20,0.08) (-0.07,0.09) (-0.08,0.08) (-0.08,0.08) (-0.08,0.09) (-0.20,-0.03) (-0.21,-0.04) (-0.21,-0.04) (-0.16,0.00) 
 0.243 0.241 0.248 0.244 0.423 0.311 0.261 0.377 0.800 0.963 0.978 0.879 0.007 0.005 0.003 0.053 
SUD 1.01 1.01 1.03 1.04 0.14 0.13 0.05 0.06 0.07 0.07 0.03 0.04 c-- -- -- -- 
 (0.83,1.22) (0.83,1.22) (0.85,1.25) (0.85,1.27) (-0.01,0.29) (-0.03,0.28) (-0.11,0.20) (-0.09,0.22) (-0.02,0.16) (-0.02,0.15) (-0.06,0.12) (-0.05,0.13) -- -- -- -- 
 0.944 0.960 0.779 0.701 0.076 0.106 0.544 0.432 0.114 0.147 0.456 0.374 -- -- -- -- 
Key: a logistic regression with Intreleukin-1 beta concentration dichotomized at the median (n=3478); b multiple regression with logarithmically transformed cytokine (n=3478) or CRP concentrations (n=3527);  
c results not reported here because of a gender interaction; OR = odds ratio; CI = confidence interval; AIC = Akaike information criterion; BPD = bipolar disorder; Dysth = dysthymia; MDD = major depressive 
disorder; Comb MDD = combined MDD; Atyp MDD = atypical MDD; Mela MDD = melancholic MDD; Unsp MDD = unspecified MDD; ADA = anxiety disorders any; SUD = substance use disorders; 
Model 1: all mental disorders simultaneously entered into the models adjusted for socio-demographic characteristics (age, sex, socio-economic status); 
Model 2: Model 1 and further adjusted for psychotropic medication (antidepressants, mood stabilizers and antipsychotics); 
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Model 3: Model 2 and further adjusted for behavioral cardiovascular risk factors (physical inactivity and smoking); 
Model 4: Model 3 and further adjusted for physical cardiovascular risk factors (BMI, diabetes, hypertension, dyslipidemia); 
The lower the AIC values, the better the goodness of fit. 
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Table 4: Associations between current mental disorders and pro-inflammatory proteins 
  
Interleukin-1β [pg/l] 
ORa 
95% CI 
p 
Interleukin-6 [pg/ml] 
βb 
95% CI 
p 
Tumor Necrosis Factor-α [pg/ml] 
βb 
95% CI 
p 
hsC-Reactive Protein [mg/l] 
βb 
95% CI 
p 
  Model 1 Model 2 Model 3 Model 4 Model 1 Model 2 Model 3 Model 4 Model 1 Model 2 Model 3 Model 4 Model 1 Model 2 Model 3 Model 4 
AIC 4812 4817 4820 4816 12641 12644 12627 12609 9369 9373 9367 9357 9856 9859 9807 9246 
Current diagnoses                             
Dysth 0.83 0.83 0.85 0.81 0.53 0.53 0.49 0.49 0.16 0.16 0.15 0.15 0.07 0.07 0.03 0.01 
 (0.34,2.01) (0.34,2.02) (0.35,2.05) (0.33,1.96) (-0.17,1.23) (-0.17,1.23) (-0.21,1.19) (-0.20,1.19) (-0.25,0.57) (-0.25,0.57) (-0.26,0.55) (-0.26,0.55) (-0.37,0.51) (-0.37,0.52) (-0.41,0.46) (-0.40,0.41) 
 0.680 0.681 0.709 0.636 0.135 0.138 0.168 0.166 0.439 0.437 0.475 0.473 0.752 0.740 0.908 0.963 
Comb 
MDD 0.81 0.82 0.83 0.84 -0.09 -0.14 -0.15 -0.20 -0.06 -0.08 -0.09 -0.10 -0.04 -0.07 -0.10 -0.20 
 (0.54,1.21) (0.55,1.24) (0.55,1.25) (0.56,1.26) (-0.41,0.22) (-0.46,0.18) (-0.47,0.17) (-0.52,0.12) (-0.25,0.12) (-0.27,0.11) (-0.27,0.10) (-0.29,0.09) (-0.24,0.16) (-0.27,0.13) (-0.30,0.10) (-0.39,-0.02) 
 0.303 0.352 0.373 0.397 0.572 0.391 0.348 0.218 0.504 0.391 0.369 0.299 0.688 0.504 0.331 0.032 
Atyp 
MDD 0.94 0.95 0.95 0.98 0.30 0.27 0.27 0.23 0.07 0.06 0.06 0.04 0.19 0.17 0.17 0.03 
 (0.62,1.42) (0.63,1.44) (0.63,1.44) (0.65,1.48) (-0.02,0.63) (-0.06,0.59) (-0.05,0.60) (-0.10,0.55) (-0.12,0.26) (-0.13,0.25) (-0.13,0.25) (-0.15,0.23) (-0.02,0.39) (-0.04,0.38) (-0.04,0.37) (-0.16,0.22) 
 0.763 0.807 0.807 0.920 0.069 0.110 0.100 0.175 0.468 0.549 0.524 0.647 0.075 0.106 0.116 0.736 
Mela 
MDD 1.17 1.18 1.18 1.18 0.12 0.08 0.09 0.12 0.04 0.03 0.03 0.04 -0.14 -0.16 -0.15 -0.09 
 (0.87,1.57) (0.87,1.61) (0.87,1.60) (0.87,1.60) (-0.11,0.36) (-0.16,0.32) (-0.15,0.33) (-0.12,0.35) (-0.09,0.18) (-0.11,0.17) (-0.11,0.17) (-0.10,0.18) (-0.28,0.01) (-0.31,-0.01) (-0.30,0.00) (-0.23,0.05) 
 0.302 0.277 0.286 0.286 0.307 0.510 0.451 0.347 0.523 0.676 0.628 0.549 0.064 0.034 0.044 0.201 
Unsp 
MDD 1.04 1.04 1.05 1.05 0.10 0.09 0.08 0.08 -0.02 -0.03 -0.03 -0.03 -0.13 -0.14 -0.15 -0.12 
 (0.80,1.35) (0.80,1.36) (0.81,1.36) (0.81,1.37) (-0.10,0.31) (-0.12,0.30) (-0.13,0.29) (-0.12,0.29) (-0.14,0.10) (-0.15,0.09) (-0.15,0.09) (-0.15,0.09) (-0.26,0.00) (-0.27,-0.01) (-0.28,-0.02) (-0.24,-0.01) 
 0.774 0.749 0.724 0.695 0.319 0.394 0.444 0.419 0.712 0.657 0.618 0.672 0.046 0.036 0.022 0.040 
ADA 0.94 0.95 0.95 0.95 -0.15 -0.15 -0.16 -0.14 -0.01 -0.01 -0.02 -0.01 -0.14 -0.14 -0.15 -0.07 
 (0.75,1.18) (0.76,1.19) (0.76,1.19) (0.76,1.19) (-0.32,0.03) (-0.33,0.03) (-0.34,0.01) (-0.32,0.04) (-0.11,0.10) (-0.12,0.09) (-0.12,0.09) (-0.11,0.10) (-0.24,-0.03) (-0.25,-0.03) (-0.25,-0.04) (-0.18,0.03) 
 0.606 0.630 0.642 0.654 0.109 0.093 0.070 0.122 0.906 0.823 0.753 0.920 0.015 0.011 0.009 0.148 
SUD 0.94 0.94 0.96 0.97 0.19 0.18 0.12 0.14 0.08 0.07 0.04 0.05 0.14 0.13 0.08 0.11 
 (0.71,1.24) (0.71,1.25) (0.72,1.27) (0.73,1.28) (-0.03,0.41) (-0.04,0.40) (-0.10,0.34) (-0.08,0.36) (-0.05,0.20) (-0.06,0.20) (-0.08,0.17) (-0.08,0.18) (0.00,0.27) (-0.01,0.26) (-0.06,0.21) (-0.01,0.24) 
  0.653 0.671 0.775 0.805 0.084 0.100 0.296 0.225 0.241 0.272 0.502 0.438 0.052 0.068 0.270 0.077 
Key: a logistic regression with Intreleukin-1 beta concentration dichotomized at the median (n=3478); b multiple regression with logarithmically transformed cytokine (n=3478) or CRP concentrations (n=3527);  
OR = odds ratio; CI = confidence interval; AIC = Akaike information criterion; Dysth = dysthymia; MDD = major depressive disorder; Comb MDD = combined MDD; Atyp MDD = atypical MDD; Mela MDD = 
melancholic MDD; Unsp MDD = unspecified MDD; ADA = anxiety disorders any; SUD = substance use disorders; 
Model 1: all mental disorders simultaneously entered into the models and adjusted for socio-demographic characteristics (age, sex, socio-economic status); 
Model 2: Model 1 and further adjusted for psychotropic medication (antidepressants, mood stabilizers and antipsychotics); 
Model 3: Model 2 and further adjusted for behavioral cardiovascular risk factors (physical inactivity and smoking); 
Model 4: Model 3 and further adjusted for physical cardiovascular risk factors (BMI, diabetes, hypertension, dyslipidemia); 
Current diagnosis of bipolar disorder not assessed due to small sample size; 
The lower the AIC values, the better the goodness of fit. 
 
25 
 
 
